Mereo BioPharma Group plc

Share Issue/Capital Change • Apr 27, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3193M

Mereo BioPharma Group plc

27 April 2018

Mereo BioPharma Group plc

("Mereo" or the "Company" or the "Group")

Grant of Options

London, 27 April 2018 - Mereo BioPharma Group plc (AIM: MPH), a multi-asset biopharmaceutical company, today announces that it has granted options over a total of 100,817 ordinary shares of £0.003 each in the capital of the Company ("Shares") on 26 April 2018 to certain directors and certain other persons discharging managerial responsibility ("PDMRs") (the "Options"), as set out below. 

The Options represent awards under the Company's Deferred Bonus Share Plan (the "DBSP") as previously disclosed in the Remuneration Report of our recently published 2017 Annual Report. The DBSP provides for the deferral of a percentage of the annual bonuses awarded to certain employees of the Company in respect of FY 2017 into the right to acquire shares in equal value to the amount deferred. These Options are nil cost options and the number of Shares subject to the Options has been calculated by reference to the share price at January 31, 2018 of 323 pence per share.

Name	Incentive Plan	No. of Ordinary Shares under Option
Denise Scots-Knight (Chief Executive Officer)	DBSP	32,205
Charles Sermon (General Counsel)	DBSP	23,966
Alastair MacKinnon (Chief Medical Officer)	DBSP	22,588
Richard Jones (Chief Financial Officer)	DBSP	22,058

Awards granted under the DBSP

Options granted under the DBSP will normally vest on the third anniversary of the date of grant, after which they will normally be exercisable for a period of one year.

For further information, please contact:

Mereo BioPharma Group plc	+44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
Richard Jones, Chief Financial Officer
Cantor Fitzgerald Europe (Nominated Adviser and Broker)	+44 (0)20 7894 7000
Phil Davies
Will Goode
Rick Thompson
RBC Capital Markets (Joint Broker)	+44 (0)20 7653 4000
Rupert Walford
Laura White
FTI Consulting (Public Relations Adviser)	+44 (0)20 3727 1000
Ben Atwell
Simon Conway
Brett Pollard
Burns McClellan (US Public Relations Advisor to Mereo Biopharma) Lisa Burns Steven Klass	+01 (0) 212 213 0006

About Mereo

Mereo is a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. The portfolio consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies: BPS-804 for the treatment of osteogenesis imperfecta; AZD-9668 for the treatment of severe alpha-1 antitrypsin deficiency; BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease, or AECOPD; and BGS-649 for the treatment of hypogonadotropic hypogonadism ("HH")  in obese men. Each of the Company's product candidates has generated positive clinical data for Mereo's target indication or in a related indication. The Company's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. Since inception the Company has commenced large, randomized, placebo-controlled Phase 2 clinical trials for three of the product candidates and announced positive top-line results from its Phase 2 clinical trial of BCT-197 as an acute therapy for patients with AECOPD in December 2017 and positive top-line data from its Phase 2b dose-ranging study with BGS-649 for the treatment of HH.

The information set out below is provided in accordance with the requirements of Article 19 of the Market Abuse Regulation (EU) No 596/2014.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1.   Denise Scots-Knight

2.   Charles Sermon

3.   Alastair MacKinnon

4.   Richard Jones

2

Reason for the notification

a)

Position/status

1.   Chief Executive Officer

2.   General Counsel

3.   Chief Medical Officer

4.   Chief Financial Officer

b)

Initial notification  / Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code:

Nil cost options over Shares of £0.003 pence each

ISIN: GB00BZ4G2K23

b)

Nature of the transaction

Grant of Award

c)

Price(s) and volume(s)

Price(s)	Volume(s)
Nil cost	1.   32,205
2.   23,966
3.   22,588
4.   22,058

d)

Aggregated information

Options over 100,817  Shares

Nil cost

e)

Date of the transaction

26 April 2018

f)

Place of the transaction

Outside a trading venue

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHFQLLLVZFZBBE